核糖体蛋白s6
克拉斯
胰腺癌
磷酸化
癌症研究
生物
DMBA公司
PI3K/AKT/mTOR通路
蛋白激酶B
癌症
P70-S6激酶1
癌变
信号转导
细胞生物学
结直肠癌
遗传学
作者
Abed Khalaileh,Avigail Dreazen,Areej Khatib,Roy Apel,Avital Swisa,Norma Kidess-Bassir,Anirban Maitra,Oded Meyuhas,Yuval Dor,Gideon Zamir
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2013-01-30
卷期号:73 (6): 1811-1820
被引量:74
标识
DOI:10.1158/0008-5472.can-12-2014
摘要
The signaling pathways that mediate the development of pancreatic ductal adenocarcinoma (PDAC) downstream of mutant Kras remain incompletely understood. Here, we focus on ribosomal protein S6 (rpS6), an mTOR effector not implicated previously in cancer. Phosphorylation of rpS6 was increased in pancreatic acinar cells upon implantation of the chemical carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) or transgenic expression of mutant Kras. To examine the functional significance of rpS6 phosphorylation, we used knockin mice lacking all five phosphorylatable sites in rpS6 (termed rpS6(P-/-) mice). Strikingly, the development of pancreatic cancer precursor lesions induced by either DMBA or mutant Kras was greatly reduced in rpS6(P-/-) mice. The rpS6 mutants expressing oncogenic Kras showed increased p53 along with increased staining of γ-H2AX and 53bp1 (Trp53bp1) in areas of acinar ductal metaplasia, suggesting that rpS6 phosphorylation attenuates Kras-induced DNA damage and p53-mediated tumor suppression. These results reveal that rpS6 phosphorylation is important for the initiation of pancreatic cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI